ABOUT YPRIME

Since 2006, YPrime has helped biopharmaceutical organizations expedite and improve the quality of patient and site management, clinical supplies, drug accountability and patient-generated data in their clinical development efforts. YPrime’s configurable and customizable IRT and eCOA platforms enable greater speed, precision and integration in clinical trial management. The company’s data services tools eliminate data silos and help sponsors bring together fragmented clinical research data into contextual and actionable information. For more information, visit https://www.yprime.com/.

FEATURED PRODUCTS

YPrime helps you decipher clinical trial complexity—delivering IRT solutions that anticipate the ever-evolving needs of the clinical development industry. Using our IRT platform, our clients can reduce the risks, burdens, complexities, workload, time and costs associated with managing all aspects of global patient randomization and clinical supply management.

YPrime’s eCOA platform features an exceptional user experience for sponsors, investigator sites, and patients. This advanced technology enhances clinical trial efficiency, increases site satisfaction, and improves patient compliance. YPrime’s eCOA platform ensures the delivery of cleaner data, streamlining the clinical trial data collection and approval process. Our platform delivers even the most complex protocol seamlessly. Developed to integrate intelligently with your other technologies, all modalities are available for site- or home-based trials.

CONTACT INFORMATION

YPrime

263 Great Valley Parkway

Malvern, PA 19355

UNITED STATES

Phone: 267-536-3329

Contact: Jennifer McAleer

FEATURED ARTICLES

  • At YPrime, we have a passion for empowering the patient through their clinical trial journey and eliminating the barriers and friction that get in their way.

  • The clinical research industry has been reluctant to adopt eConsent for several reasons, not least of which included having to disrupt already stressed and short-staffed work environments to implement new technology. Read how the industry should continue exploring and implementing digital technologies in earnest.

     
  • The proliferation of both patient-centric and hybrid clinical trials has created a need for more individualized, simplified, accessible processes involving trial participants.

  • When the COVID-19 pandemic hit the U.S. in March 2020, many drug developers were caught by surprise. With clinics overwhelmed by COVID patients and the reluctance of some patients to venture out to those clinics, many trials faced the prospect of being delayed or canceled. Decentralized clinical trials (DCTs) and hybrid trials, which can take studies from the clinics to the patients, seemed to be the solution to keep things on track.

  • When the COVID-19 pandemic hit the U.S. in March 2020, many drug developers were caught by surprise. With clinics overwhelmed by COVID patients and the reluctance of some patients to venture out to those clinics, many trials faced the prospect of being delayed or canceled. Decentralized clinical trials (DCTs) and hybrid trials, which can take studies from the clinics to the patients, seemed to be the solution to keep things on track.

  • When the COVID-19 pandemic hit the U.S. in March 2020, many drug developers were caught by surprise. With clinics overwhelmed by COVID patients and the reluctance of some patients to venture out to those clinics, many trials faced the prospect of being delayed or canceled. Decentralized clinical trials (DCTs) and hybrid trials, which can take studies from the clinics to the patients, seemed to be the solution to keep things on track.

  • When the COVID-19 pandemic hit the U.S. in March 2020, many drug developers were caught by surprise. With clinics overwhelmed by COVID patients and the reluctance of some patients to venture out to those clinics, many trials faced the prospect of being delayed or canceled. Decentralized clinical trials (DCTs) and hybrid trials, which can take studies from the clinics to the patients, seemed to be the solution to keep things on track.

  • When the COVID-19 pandemic hit the U.S. in March 2020, many drug developers were caught by surprise. With clinics overwhelmed by COVID patients and the reluctance of some patients to venture out to those clinics, many trials faced the prospect of being delayed or canceled. Decentralized clinical trials (DCTs) and hybrid trials, which can take studies from the clinics to the patients, seemed to be the solution to keep things on track.

  • Patients are even more digital-savvy and exposed to sophisticated technology. This presents a huge opportunity to incorporate patient engagement into clinical trials and elevate patient engagement efforts in ongoing clinical trials.

  • At YPrime, we’re here to help you make a positive impact by bringing live-changing therapies to market.

  • As the clinical research ecosystem continues to expand and include the perspectives of research partners, stakeholders, and patients and caregivers, learn why collaboration and connection is essential to future clinical trial success and next-generation medicine.

  • Learn how supporting patients’ participation in completing study requirements can ease the burden on both patients and their care partners when it comes to decentralized trials.

  • When it comes to patient engagement, the experience and technology gaps apparent in the clinical trial space have resulted in a lag for virtual technologies that offer comparable functionality to those pioneered by other sectors.

  • This webinar addresses lessons the eClinical space can learn from consumer engagement, how to "scale" empathy using eClinical applications, and how consumer engagement methods can be used in eClinical applications to engage, incentivize, and motivate patients in clinical trials

  • Technology is critical to clinical trial efficiency and data quality, particularly for supporting the increased operational complexities of research. Discover ways to think broadly about the effective implementation of technology.

  • Find out how the shift left testing principles focus on continuous integration and delivery, a practice designed to find and prevent defects early in the software delivery process.

  • Learn why DCT solutions must be considered while identifying and prioritizing how a strategy or technology grants efficiencies in one area while generating complex issues in another.

  • Data governance aligns people, processes, and information technology in order to optimize the use and value of data across a business enterprise. Discover how this formal practice helps sponsors collect, integrate, and analyze data strategically to advance their drug development programs.

  • Regulators across the globe are urging the industry to strengthen their data integrity practices. This article addresses the additional considerations that go hand in hand with the increased reliance on eSource data and the expansion of the electronic systems in clinical trials.

  • As the use of eCOA expands to incorporate more submission-critical elements, especially key endpoints and factors contributing to protocol analyses, learn how customized compliance strategies are more important than ever to ensure data integrity.